002252.SHE Shanghai RAAS Blood Products Co Ltd Class A
- Market cap
- CNY 32.0B
- P/E
- 28.5x
- P/B
- 0.96x
- ROE
- 4.0%
- Dividend yield
- 0.99%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 002252.SHE undervalued?
Graham number002252.SHE trades 10.3% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Shanghai RAAS Blood Products Co Ltd Class A fundamental analysis
No fundamental analysis for Shanghai RAAS Blood Products Co Ltd Class A yet.
Shanghai RAAS Blood Products Co Ltd Class A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Shanghai RAAS Blood Products Co Ltd Class A
Shanghai RAAS Blood Products Co., Ltd., together with its subsidiaries, produces and sells blood products in China and internationally. The company offers ALBURAAS, which is albumin prepared from human plasma; GAMARAAS, a human immunoglobulin product for intravenous injections; HEMORAAS, a human coagulation factor VIII product; PROTHORAAS, a human prothrombin complex; FIBRORAAS, a human fibrinogen; FIBINGLURAAS, a fibrin sealant for humans; and THROMBIRAAS, a human thrombin …
Full company profileShanghai RAAS Blood Products Co Ltd Class A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Shanghai RAAS Blood Products Co Ltd Class A annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 2.33B | 1.93B | 1.80B | 2.58B | 2.76B | 4.29B | 6.57B | 7.96B | 8.18B | 7.35B | 6.59B |
| Gross Profit | 1.48B | 1.22B | 1.19B | 1.65B | 1.70B | 2.22B | 2.89B | 3.23B | 3.30B | 2.75B | 2.35B |
| Operating Income | 1.95B | 1.01B | -1.75B | 736M | 1.50B | 1.55B | 2.28B | 2.23B | 2.68B | 1.91B | 1.23B |
| EBITDA | 1.21B | 907M | 584M | 1.04B | 1.17B | 1.62B | 2.17B | 2.48B | 2.29B | 1.82B | 1.64B |
| Net Income | 1.61B | 836M | -1.52B | 608M | 1.32B | 1.29B | 1.88B | 1.78B | 2.19B | 1.58B | 1.31B |
| EPS | 0.33 | 0.17 | -0.31 | 0.12 | 0.20 | 0.19 | 0.28 | 0.27 | 0.33 | 0.24 | 0.20 |
| Balance Sheet | |||||||||||
| Total Assets | 13.2B | 14.5B | 11.4B | 11.9B | 25.5B | 27.2B | 30.5B | 31.9B | 33.6B | 37.8B | 37.7B |
| Total Liabilities | 1.50B | 1.98B | 497M | 362M | 364M | 1.33B | 1.64B | 2.28B | 1.69B | 5.34B | 5.24B |
| Shareholders' Equity | 11.7B | 12.5B | 10.9B | 11.5B | 25.1B | 25.9B | 28.8B | 29.6B | 31.9B | 32.5B | 32.5B |
| Cash & Short-term Investments | 4.24B | 4.52B | 1.19B | 1.73B | 2.21B | 2.96B | 4.22B | 4.20B | 4.63B | 2.11B | 1.34B |
| Total Debt | 384M | 360M | 150M | - | 7.74M | 4.16M | 1.85M | 1.49M | 13.0M | 3.95B | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 638M | 269M | 263M | 873M | 1.17B | 1.29B | 1.73B | 2.28B | -482M | -105M | - |
| Capital Expenditure | 147M | 158M | 157M | 155M | 252M | 205M | 226M | 451M | 407M | 379M | 406M |
| Free Cash Flow | 491M | 107M | 106M | 718M | 917M | 1.09B | 1.50B | 1.83B | -889M | -484M | -160M |
| Ratios | |||||||||||
| ROE | 13.8% | 6.7% | -13.9% | 5.3% | 5.3% | 5.0% | 6.5% | 6.0% | 6.9% | 4.9% | 4.0% |
| ROA | 12.2% | 5.8% | -13.3% | 5.1% | 5.2% | 4.8% | 6.2% | 5.6% | 6.5% | 4.2% | 3.5% |
| Net Profit Margin | 69.3% | 43.4% | -84.2% | 23.5% | 47.9% | 30.2% | 28.6% | 22.3% | 26.8% | 21.5% | 19.8% |
| Debt to Equity | 0.03x | 0.03x | 0.01x | - | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.12x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Shanghai RAAS Blood Products Co Ltd Class A dividends
- Dividend yield
- 0.99%
- Forward dividend
- 0.05 CNY
- Payout ratio
- 20.2%
- Ex-dividend date
- Jun 24, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 318M | 0.05 | 20.2% |
| 2024 | CNY 440M | 0.07 | 20.1% |
| 2023 | CNY 202M | 0.03 | 11.4% |
| 2022 | CNY 189M | 0.03 | 10.0% |
| 2021 | CNY 169M | 0.03 | 13.0% |
| 2020 | CNY 67.8M | 0.01 | 5.1% |
| 2019 | CNY 1.60M | 0.00 | 0.3% |
| 2018 | CNY 167M | 0.03 | - |
| 2017 | CNY 218M | 0.04 | 26.1% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 18:10 on Sep 28, 2016.
Who owns Shanghai RAAS Blood Products Co Ltd Class A
- Insiders 32.47%
- Institutions 22.79%
- Public & others 44.73%
- Shares outstanding 6.59B
- Free float 4.47B
Shanghai RAAS Blood Products Co Ltd Class A company profile
- Company name
- Shanghai RAAS Blood Products Co Ltd Class A
- Ticker
- 002252.SHE
- ISIN
- CNE100000C31
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Jun 23, 2008
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 4,045
- Fiscal year end
- December
- Address
- No. 2009, Wangyuan Road, Shanghai, China, 201401
- Phone
- 86 21 2213 0888
- Website
- raas-corp.com
About Shanghai RAAS Blood Products Co Ltd Class A
Shanghai RAAS Blood Products Co., Ltd., together with its subsidiaries, produces and sells blood products in China and internationally. The company offers ALBURAAS, which is albumin prepared from human plasma; GAMARAAS, a human immunoglobulin product for intravenous injections; HEMORAAS, a human coagulation factor VIII product; PROTHORAAS, a human prothrombin complex; FIBRORAAS, a human fibrinogen; FIBINGLURAAS, a fibrin sealant for humans; and THROMBIRAAS, a human thrombin product. It also provides specific immune, human tetanus immunoglobulin, human rabies immunoglobulin, human immunoglobulin, hepatitis B human immunoglobulin, and other blood products. The company exports its products. Shanghai RAAS Blood Products Co., Ltd. was founded in 1988 and is headquartered in Shanghai, China.
Shanghai RAAS Blood Products Co Ltd Class A management
9- Mr. Jun XuGM & Vice Chairman · born 1964
- Mr. Leqi ChenHead of Finance · born 1987
- Mr. Zheng LiuDeputy GM & Secretary of Board of Directors · born 1970
- Mr. Ji Hui ShenDeputy General Manager · born 1966
- Mr. Hui LuDeputy General Manager · born 1975
- Ms. Zhengmin SongDeputy General Manager · born 1968
- Mr. Qin Bing HuangDeputy General Manager · born 1977
- Ms. Xi ZhaoHead of Accounting
- Mr. Yang Gu M.D.Director of Sales & Marketing